Walk into a large hospital before dawn and the place is already producing a small weather system of data. A CT scanner finishes a trauma study. An ultrasound probe measures a heart. A bedside monitor catches a pressure change. A contrast agent makes anatomy legible. The images and numbers then travel through separate screens, departments and decisions, often with a human carrying the context between them. GE HealthCare has spent more than a century building much of this machinery. Its newer ambition is to make the pieces behave less like islands.
That is a bigger change than adding AI to a scanner. GE HealthCare is trying to join three businesses that operate on different clocks: durable medical equipment bought through capital budgets, diagnostic pharmaceuticals consumed one procedure at a time, and software that is updated continuously. The company can put an algorithm on the device, move the resulting image through a cloud workflow, combine it with prior clinical data and maintain the system afterward. Few competitors can cover that full trip.
01 / IDENTITYThe oldest new company in medicine
GE HealthCare Technologies Inc. is technically young. General Electric formed the holding company in May 2022 and completed the spin-off on January 3, 2023, when shares began trading independently on Nasdaq. Yet the operating lineage runs back to 1896, when GE co-founder Elihu Thomson built X-ray equipment and demonstrated stereoscopic fracture imaging. That makes GE HealthCare an unusual corporate creature: a three-year-old public company with a 130-year product memory.
The distinction matters. Independence gave management its own capital allocation, acquisitions and investor story. The inherited installed base gave it distribution that a software startup cannot buy quickly. GE HealthCare says more than five million pieces of its equipment are installed worldwide and its products or care solutions touch more than one billion patients each year. Every machine is a clinical tool, but also a possible endpoint for software, service and regulated AI.
02 / PORTFOLIOMachines, molecules and a lot of middlewear
The hardware catalog is broad enough to furnish entire departments: MRI and CT systems, X-ray and fluoroscopy, mammography, PET/CT and SPECT/CT, surgical and interventional imaging, ultrasound, patient monitors, anesthesia delivery, diagnostic ECG, and maternal and infant-care equipment. Vscan Air puts wireless ultrasound in a clinician's hand. Omni Legend handles PET/CT. StarGuide brings digital detectors to SPECT/CT. The names vary by specialty, but the practical promise is similar: capture a useful signal while reducing steps around the exam.
Pharmaceutical Diagnostics is the less visible companion. Its contrast media and molecular imaging agents help make anatomy or biology readable during scans. The division produced more than 110 million doses a year and says its products support roughly four patient procedures every second. That gives GE HealthCare a recurring, procedure-linked business next to machines that hospitals may keep for years.
Then comes the software layer. CareIntellect offers a common data foundation for clinical and operational applications. Command Center products help hospitals watch capacity, patient flow and bottlenecks. MIM Software provides analysis and workflow tools in oncology, nuclear medicine and other imaging fields. Introduced in July 2026, MIM Anyware makes those applications available through a browser under health-system control. This is not consumer software wearing a lab coat. It has to respect clinical permissions, integrate with hospital systems, remain available and survive regulatory scrutiny.
The most valuable image is not merely sharper. It arrives with context, reaches the right clinician and does not create three new logins along the way.
03 / PROBLEMThe hospital already has data. It needs choreography.
Healthcare's constraint is rarely a shortage of measurements. It is fragmentation. Imaging archives, scheduling systems, monitors and clinical records may use different interfaces and refresh at different speeds. Specialists can be scarce. Appointment gaps waste expensive equipment time. Repetitive setup and documentation pull clinicians away from patients. Meanwhile, cyber risk makes every new connection a possible liability.
GE HealthCare attacks that problem at three levels. AI inside a device can automate measurements or guide image acquisition. Departmental software can route studies, orchestrate algorithms and reduce manual work. Enterprise tools can expose bottlenecks across beds, scanners and schedules. The company reported 132 AI-enabled device authorizations on the FDA's public list as of June 2026. The useful part is not the number by itself. It is the ability to distribute regulated tools through equipment and workflows that clinicians already know.
04 / CUSTOMERSSelling to the whole health system
The obvious customers are radiology departments and hospitals, but the actual map is wider: integrated health systems, outpatient imaging centers, cardiology and oncology practices, researchers, pharmaceutical developers, governments and ministries of health. Buyers range from a sonographer choosing a probe to a chief financial officer planning a ten-year capital program. A product has to satisfy clinicians, biomedical engineers, IT security teams, procurement officers and regulators before it ever meets a patient.
That is why GE HealthCare increasingly sells relationships rather than boxes. In July 2026, Catholic Health on Long Island signed a 10-year Care Alliance valued at about $500 million. The plan covers more than 1,300 technologies across hospitals and ambulatory locations, combining imaging and diagnostics with AI-enabled tools and service. For the customer, this turns a parade of replacement purchases into a modernization program. For GE HealthCare, it creates a longer commercial horizon and room to attach software, training and maintenance.
The company finished the second quarter of 2026 with a record $23.9 billion backlog and 11.1 percent organic orders growth. Backlog is not revenue, and hospital projects can move slowly, but it signals demand across unusually long buying cycles. It also helps explain why service matters: the relationship continues well after the installation crew leaves.
Scanners, monitors and clinical systems sold through hospital investment budgets.
Maintenance, parts, fleet analytics, training and multi-year lifecycle support.
Contrast media and molecular imaging agents consumed as patient volume moves.
Subscriptions, licenses and cloud applications with a growing recurring profile.
05 / EDGEA moat made of installed equipment
Siemens Healthineers and Philips are the closest broad rivals. Canon Medical, Fujifilm and Mindray compete across selected device categories; Bayer and Bracco in contrast media; Sectra and other specialists in enterprise imaging. GE HealthCare does not win every modality or every hospital. Its distinction is the span between them. It can combine the imaging system, diagnostic agent, visualization software, AI, service organization and financing in one proposal.
That breadth creates its own risk. A platform story only works if the parts integrate cleanly. Hospitals are full of equipment from multiple vendors and will resist lock-in that limits clinical choice. GE HealthCare must support interoperability while proving that its own stack works better together. It must also modernize long-lived devices without turning every upgrade into a capital project.
The $2.3 billion acquisition of Intelerad, completed in March 2026, is a direct response. GE HealthCare was already strong inside hospital imaging departments. Intelerad adds cloud PACS, image exchange, workflow orchestration and teleradiology, with a large outpatient and ambulatory presence and a mostly recurring revenue base. Medical images increasingly travel beyond the building where they were captured. GE HealthCare bought more of that route.
06 / MARKETFrom modality to care pathway
The medical-technology market is traditionally organized by machine: an MRI team, a CT team, an ultrasound team. GE HealthCare is trying to reorganize the commercial story around diseases and care pathways. In cancer, for example, molecular imaging can detect disease, software can quantify lesions, radiopharmaceuticals can support diagnosis, and theranostics can connect imaging with targeted treatment. In cardiology, ultrasound, ECG, interventional imaging and workflow software can follow a patient through different rooms and decisions.
Partnerships fill gaps the company cannot close alone. AWS supplies cloud and foundation-model infrastructure. NVIDIA is working with GE HealthCare on more autonomous X-ray and ultrasound systems. Mayo Clinic collaborates on MRI, ultrasound and theranostics research. Mass General Brigham contributes clinical AI expertise and real-world workflows. DeepHealth brings breast-imaging algorithms. This is not charitable openness; it is how a large regulated company gets specialized technology and clinical feedback into products faster.
The culture GE HealthCare advertises is built around a lean mindset, entrepreneurial spirit, accountability and belonging. Approximately 54,000 colleagues work across more than 160 countries, with 11,000-plus granted patents behind the portfolio. The harder cultural task is joining hardware cadence with software cadence. A scanner platform may live for a decade. A cloud service may change monthly. Clinical evidence and cybersecurity have to keep pace with both.
Elihu Thomson builds X-ray equipment, placing the business near the beginning of medical imaging.
Vscan puts ultrasound into a pocket-sized device and moves imaging closer to the bedside.
GE HealthCare separates from General Electric and begins independent trading on Nasdaq.
Intelerad joins the portfolio; the company reports a record backlog and launches MIM Anyware.
07 / OUTLOOKThe handoff is the product
GE HealthCare reported $20.625 billion in 2025 revenue. In the second quarter of 2026, revenue rose 5.7 percent to $5.3 billion, led by Advanced Imaging and Pharmaceutical Diagnostics, while Patient Care Solutions remained challenged. Management said it was reviewing strategic options for that unit. The mixed performance is a reminder that a broad portfolio is not automatically a balanced one.
Still, the strategic direction is legible. The company wants more recurring revenue, more cloud delivery and more intelligence placed close to a clinical decision. It is investing in AI without pretending that hospitals can be rebuilt around a single model. The practical work is smaller and more stubborn: fewer clicks, faster image access, a missed appointment predicted early enough to fill the slot, a probe that helps a novice acquire a usable view, a scanner that stays available.
For a patient, the GE name may appear briefly on a gantry or monitor. The more consequential work happens out of sight, in the transfer between acquisition, interpretation and action. GE HealthCare's future depends on making that transfer reliable enough that nobody notices it. In a hospital, invisibility can be a very good product.